Tesofensine
Purrptide digest
Tesofensine started life as a Parkinson's and Alzheimer's drug candidate, blocking reuptake of dopamine, noradrenaline, and serotonin all at once. During trials, researchers noticed significant unintended weight loss — a strong enough effect that the drug pivoted entirely toward obesity treatment. A Phase 2 obesity trial showed greater weight loss than most approved drugs at the time, though it hasn't yet reached the same regulatory finish line as the GLP-1 class.
What this means for you
Not yet approved for weight loss anywhere, but the Phase 2 numbers were genuinely competitive with established options. Worth watching its approval status.
A triple monoamine reuptake inhibitor mechanism is completely different from GLP-1 drugs — a genuinely distinct pharmacological category for obesity.
Repurposing a neurological drug candidate into a metabolic one based on an incidental trial finding is a good case study in serendipitous drug discovery.
A non-GLP-1 weight-loss mechanism with strong early data is a differentiated bet in a category currently dominated by one drug class.
For the nerds
Effect of tesofensine on bodyweight loss, body composition, and quality of life
The Lancet · DOI: 10.1016/S0140-6736(08)61525-1
Read full paper on PubMed →